BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...midyear.Provention, Huadong partner on autoimmune bispecific in ChinaProvention Bio Inc. (NASDAQ:PRVB) partnered with Hangzhou Zhongmei Huadong Pharmaceutical...
BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

...SORAYA study of ADC mirvetuximab soravtansine, and thinks accelerated approval could come in 2022. Last week, Huadong Medicine Co. Ltd....
...IMGN853) MORAb-202 STRO-002 TPIV200 (TPIV 200, TPIV200/huFR-1) Folate receptor alpha peptide vaccine ImmunoGen Inc. Eisai Co. Ltd. Sutro Biopharma Inc. Marker Therapeutics Inc. Mayo Clinic Huadong Medicine Co. Ltd. Epsilogen...
BioCentury | Oct 19, 2020
Deals

ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC

...million up front, one of the higher sums paid for a clinical-stage cancer asset’s local rights.Huadong Medicine Co. Ltd....
...2020.ImmunoGen slipped $0.10 to $5.65 on Monday.TARGETSFOLR1 (FR-α; FOLR) - Folate receptor 1 Paul Bonanos mirvetuximab soravtansine (IMGN853) Huadong Medicine Co. Ltd. ImmunoGen...
Items per page:
1 - 3 of 3
BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...midyear.Provention, Huadong partner on autoimmune bispecific in ChinaProvention Bio Inc. (NASDAQ:PRVB) partnered with Hangzhou Zhongmei Huadong Pharmaceutical...
BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

...SORAYA study of ADC mirvetuximab soravtansine, and thinks accelerated approval could come in 2022. Last week, Huadong Medicine Co. Ltd....
...IMGN853) MORAb-202 STRO-002 TPIV200 (TPIV 200, TPIV200/huFR-1) Folate receptor alpha peptide vaccine ImmunoGen Inc. Eisai Co. Ltd. Sutro Biopharma Inc. Marker Therapeutics Inc. Mayo Clinic Huadong Medicine Co. Ltd. Epsilogen...
BioCentury | Oct 19, 2020
Deals

ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC

...million up front, one of the higher sums paid for a clinical-stage cancer asset’s local rights.Huadong Medicine Co. Ltd....
...2020.ImmunoGen slipped $0.10 to $5.65 on Monday.TARGETSFOLR1 (FR-α; FOLR) - Folate receptor 1 Paul Bonanos mirvetuximab soravtansine (IMGN853) Huadong Medicine Co. Ltd. ImmunoGen...
Items per page:
1 - 3 of 3